PATENT

Attorney Docket No.: VOSS1130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mapplicant:

Peltonen, et al.

Art Unit:

1653

Application No.:

09/509,595

Examiner

Carlson, K.

Filed:

July 5, 2000

Title: NUCLEI

NUCLEIC ACID MOLECULE ENCODING A (POLY)PEPTIDE CO-

SEGREGATING IN MUTATED FORM WITH AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL

DYSTROPHY

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS UNDER 37 C.F.R. §§ 1.821-1.825

Dear Sir:

In response to the notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures mailed January 17, 2001, Applicant provides herewith a computer readable and a paper copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821 et seq.

Please amend the application as follows:

In the Specification:

Following the abstract, please insert the attached Sequence Listing with subsequent page numbering thereafter.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 15, 2001</u>, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Linda Jonkers-Yocom

Name of Person Mailing Paper

Male Male Market Standard

2.15.01

Date

In re Application of: Peltonen, et al. Application No.: 09/509,595

Filed: July 5, 2000

Page 2



PATENT Attorney Docket No.: VOSS11300

12eg. No. _____37,643

If the Examiner would like to discuss any of the issues raised in this Amendment or the attached sequence listing, Applicants' representative can be reached at (858) 677-1456.

Respectfully submitted,

Date: / elemany 15, 2001

Lisa A. Haile, Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456 Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1600 San Diego, CA 92121-2189

PATENT

Attorney Docket No.: VOSS1130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant:

Peltonen, et al.

Art Unit:

1653

MAR 0 1 2001

Application No.:

09/509,595

Examiner

Carlson, K.

TECH CENTER 1600/2900

Filed: Title:

FEB 2 1 2001

July 5, 2000

NUCLEIC ACID MOLECULE ENCODING A (POLY)PEPTIDE CO-

SEGREGATING IN MUTATED FORM WITH AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL

DYSTROPHY

Commissioner for Patents Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

Sir:

I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

Respectfully submitted,

Date: Thomany 15

Reg. No. 38,347

Telephone: (858) 677-1456 Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1600 San Diego, CA 92121-2189

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, February 15, 2001, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

Gray Cary\GT\6224260.1 104659-158041



PATENT Attorney Docket No.: VOSS1130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Peltonen, et al.

Art Unit:

1653

Application No.:

09/509,595

Examiner

Carlson, K.

Filed:

July 5, 2000

Title:

NUCLEIC ACID MOLECULE ENCODING A (POLY)PEPTIDE CO-

SEGREGATING IN MUTATED FORM WITH AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL

DYSTROPHY

Commissioner for Patents Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

I, Donald Selway, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

0 (

Donald Selway

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1600 San Diego, CA 92121-2189

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 15, 2001</u>, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

Buda Jonkers- 4000M

FEB 2 1 2001

Application No.: <u>09/509595</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Applicant Must Provide:	
×	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212
	Patentln software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE